ScripThe market for initial public offerings in the US heated up in September with five biopharmaceutical companies launching IPOs, the second busiest month for first-time offerings in 2024 after there wer
ScripScholar Rock, LLC unveiled Phase III data on 7 October that appears to make a strong case for its selective myostatin inhibitor apitegromab as additive therapy that can improve motor function in pati
ScripBiohaven Ltd. is hoping it will have better luck this time around as it prepares to apply for US Food and Drug Administration approval of troriluzole in spinocerebellar ataxia (SCA) based on a real-w
Pink SheetThe increased risks of using a celebrity for drug promotion emerged in a new US Food and Drug Administration advertising and promotion untitled letter for AbbVie Inc. ’s migraine drug Ubrelvy. Cele